Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Karen Fusaro"'
Autor:
Myreen Tomas, Alina Jucov, Igor Anastasiy, Lauren Ogilvie, Karen Fusaro, Katherine Squires, Douglas Mayers
Publikováno v:
Journal of Hepatology. 77:S73
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64c665f5584da92da8e9773b2a25a3c6
https://doi.org/10.1016/s0168-8278(22)00542-6
https://doi.org/10.1016/s0168-8278(22)00542-6
Autor:
Mark Redell, Cynthia Kennedy, Karen Fusaro, Stephanie Durso, Jeff Loutit, Greg Moeck, Christopher Lucasti, Michael N. Dudley
Publikováno v:
Open Forum Infectious Diseases
Background Oritavancin is a lipoglycopeptide used in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. To characterize its use in patients in the postapproval setting, a patient registry was developed. Methods D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5b077cbc8fc4ae0cc2dd56c052deebd
https://pubmed.ncbi.nlm.nih.gov/29977954
https://pubmed.ncbi.nlm.nih.gov/29977954
Autor:
Jeffery Loutit, Richard G. Wunderink, Karen Fusaro, Shu Zhang, Elizabeth Alexander, Mario Tumbarello, Dan White, Michael N. Dudley, Timothy Felton, George L. Daikos
Publikováno v:
Alexander, E L, Loutit, J, Tumbarello, M, Wunderink, R, Felton, T, Daikos, G, Fusaro, K, White, D, Zhang, S & Dudley, M N 2017, ' Carbapenem-resistant Enterobacteriaceae infections : Results from a retrospective series and implications for the design of prospective clinical trials ', Open Forum Infectious Diseases, vol. 4, no. 2, ofx063 . https://doi.org/10.1093/ofid/ofx063
Open Forum Infectious Diseases
Open Forum Infectious Diseases
Background The increasing incidence of multidrug-resistant Gram negatives, such as carbapenem-resistant Enterobacteriaceae (CRE), has resulted in a critical need for new antimicrobials. Most studies of new antimicrobials have been performed in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbc88bab9cf5e04b4a431ea18742004a
https://doi.org/10.1093/ofid/ofx063
https://doi.org/10.1093/ofid/ofx063
Autor:
Mark A.J. Bayliss, Stefanie Hamacher, Andrew M. Lovering, Dorothee Arenz, Karen Fusaro, Elizabeth E. Morgan, Oliver A. Cornely, Jeffery S. Loutit, Sue Cammarata, Vassiliki Dimitriou, David C. Griffith, Olivier Barraud, Alasdair P. MacGowan
Publikováno v:
Open Forum Infectious Diseases
Background Carbapenem-resistant Acinetobacter baumannii infections are defined by the WHO as a critical threat. IV minocycline is approved in the United States for treatment of Acinetobacter infections at doses up to 200 mg BID. This study investigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::875ab09dc497051a04cef25359f941a9
http://europepmc.org/articles/PMC6252552
http://europepmc.org/articles/PMC6252552
Autor:
Elizabeth E. Morgan, David A. Griffith, Shu Zhang, Karen Fusaro, Olga Lomovskaya, Elizabeth Alexander, Michael N. Dudley, Jeff Loutit
Publikováno v:
Open Forum Infectious Diseases. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce809917b27ec32f91c0a29a044c87ca
https://doi.org/10.1093/ofid/ofw195.07
https://doi.org/10.1093/ofid/ofw195.07
Autor:
Jeff Loutit, Michael N. Dudley, Karen Fusaro, Carlos Sanabria, Brooke Lohse, S. Eralp Bellibas
Publikováno v:
Open Forum Infectious Diseases. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00193281d24801c0aebda3e9d704dc4b
https://doi.org/10.1093/ofid/ofw172.1502
https://doi.org/10.1093/ofid/ofw172.1502
Autor:
David C. Griffith, Antonio Arrieta, John S. Bradley, Karen Fusaro, Jeffrey S Loutit, Paula M. Bokesch
Publikováno v:
Open Forum Infectious Diseases
Background Oritavancin (ORI) is a lipoglycopeptide antibiotic approved in adults as a single 1,200 mg intravenous (IV) dose for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Gram-positive organisms, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e92c265a6430eefd0c64a7dc919cb0
http://europepmc.org/articles/PMC6252426
http://europepmc.org/articles/PMC6252426
Autor:
Juan Pablo Horcajada, Michael N. Dudley, Elizabeth Alexander, Susan C Bleasdale, Evangelos J. Giamarellos-Bourboulis, Olga Lomovskaya, Olexiy S. Sagan, Tanaya Bhowmick, Ventsislav Stoev, Erik Chorvat, Valerii Zaitsev, Jeffery Loutit, Claudia Murta, Petru Octavian Dragoescu, Elena Fedosiuk, Symeon Metallidis, David E. Griffith, Viktor Stus, Mohamed Bidair, Karen Fusaro, Jose A. Vazquez, Yaroslav V Sarychev, Elizabeth E. Morgan, Keith S Kaye
Publikováno v:
JAMA. 319:788
Meropenem-vaborbactam is a combination carbapenem/beta-lactamase inhibitor and a potential treatment for severe drug-resistant gram-negative infections.To evaluate efficacy and adverse events of meropenem-vaborbactam in complicated urinary tract infe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f655fc09a78a49e263eaf10d394bdae8
https://doi.org/10.1001/jama.2018.0438
https://doi.org/10.1001/jama.2018.0438
Publikováno v:
Open Forum Infectious Diseases. 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::486cf02087e41b2287ecb591a7786c19
https://doi.org/10.1093/ofid/ofv133.490
https://doi.org/10.1093/ofid/ofv133.490